ANI Pharmaceuticals ANIP Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $92.15M+17.6% | $78.34M+93.1% | $40.57M+497% | -$10.21M+51.5% | -$21.05M-13.6% | ||
| $89.45M-2.2% | $91.42M0.0% | $91.4M+8.1% | $84.52M+11.3% | $75.94M+12.1% | ||
| $39.25M+3.5% | $37.93M+7.7% | $35.22M+6.7% | $33.02M+5.6% | $31.28M+6.6% | ||
| $20.14M+41.4% | $14.24M+352% | -$5.65M+81.2% | -$30.04M-5.8% | -$28.4M-29.6% | ||
| $1.39M+2.5% | $1.36M+2.1% | $1.33M+19.7% | $1.11M+28.4% | $864K+34.6% | ||
| $34.78M-40.6% | $58.53M+4.2% | $56.19M+170% | $20.78M— | —— | ||
| —— | —— | $10.37M+21.0% | $8.57M-55.5% | $19.27M-9.5% | ||
| —— | —— | —— | —— | —— | ||
| -$1.61M-132% | $5.02M— | —— | —— | —— | ||
| -$9.36M+41.5% | -$16M— | —— | —— | —— | ||
| $9.5M+236% | $2.82M— | —— | —— | —— | ||
| $1.76M+0.1% | $1.76M+10.2% | $1.6M-1.6% | $1.62M+1.1% | $1.61M+5.2% | ||
| $208.61M+12.6% | $185.23M+8.5% | $170.72M+22.7% | $139.14M+72.3% | $80.74M+26.1% | ||
| $17.44M+26.0% | $13.84M-7.7% | $14.99M+9.4% | $13.69M-3.1% | $14.13M-13.0% | ||
| $8.36M-59.2% | $20.49M+0.4% | $20.41M-2.7% | $20.98M+16.0% | $18.09M+2,423% | ||
| -$25.8M+24.8% | -$34.32M+21.3% | -$43.6M+90.0% | -$435.96M-0.6% | -$433.5M-7.1% | ||
| $751K-35.1% | $1.16M-26.0% | $1.56M-3.8% | $1.63M0.0% | $1.63M0.0% | ||
| $21.96M+79.9% | $12.21M+2.5% | $11.92M+3.2% | $11.55M-6.1% | $12.3M+12.2% | ||
| $2.03M— | $0-100% | $297.09M+0.7% | $295.06M+0.4% | $293.78M+0.4% | ||
| -$332K— | $0-100% | $13.57M+259% | $3.78M+6,725% | -$57K— | ||
| —— | —— | —— | $279.38M-0.1% | $279.67M+3.6% | ||
| $220K+194% | -$233K-132% | $725K+880% | $74K+110% | -$767K-63.2% | ||
| $161.38M+14.7% | $140.73M+19.6% | $117.63M+628% | -$22.28M+71.7% | -$78.76M-3.3% | ||
| $25.86M-4.0% | $26.93M-2.0% | $27.47M+24.4% | $22.09M-12.8% | $25.33M+3.9% | ||
| $11.32M-35.9% | $17.67M-4.3% | $18.46M+0.7% | $18.33M-0.9% | $18.49M-3.0% | ||
| $1.39M+2.5% | $1.36M+2.1% | $1.33M+19.7% | $1.11M+28.4% | $864K+34.6% | ||
| -$20.38M+36.9% | -$32.29M-13.5% | -$28.46M-116% | -$13.16M-2.8% | -$12.8M-1,968% | ||
| $15.77M-35.5% | $24.44M-5.8% | $25.95M+28.8% | $20.16M+58.1% | $12.75M+107% | ||
| -$1.61M-132% | $5.02M— | —— | —— | —— | ||
| $1.09M-89.8% | $10.73M-30.9% | $15.54M+8.7% | $14.29M+56.8% | $9.12M+0.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $4.38M-47.7% | ||
| $1.76M+0.1% | $1.76M+10.2% | $1.6M-1.6% | $1.62M+1.1% | $1.61M+5.2% | ||
| $89.45M-2.2% | $91.42M0.0% | $91.4M+8.1% | $84.52M+11.3% | $75.94M+12.1% | ||
| $8.36M-59.2% | $20.49M+0.4% | $20.41M-2.7% | $20.98M+16.0% | $18.09M+2,423% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $191.17M+11.5% | $171.39M+10.1% | $155.73M+24.1% | $125.44M+88.3% | $66.61M+39.4% | ||
| $191.17M+11.5% | $171.39M+10.1% | $155.73M+24.1% | $125.44M+88.3% | $66.61M+39.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ANI Pharmaceuticals generate?
- ANI Pharmaceuticals (ANIP) generated $208.6M in operating cash flow over the trailing twelve months.
- What is ANI Pharmaceuticals's free cash flow?
- After $17.4M of capital expenditures, ANI Pharmaceuticals's free cash flow was $191.2M over the trailing twelve months, up 187.0% year over year.
- Where does ANI Pharmaceuticals's cash flow data come from?
- Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
